(Total Views: 465)
Posted On: 04/25/2021 10:09:07 AM
Post# of 153903
Dr Nader P. knows that the Philippines is about to approve and order LL.
So why wasn't he excited about that on the ProActive video on Thursday (or was it Friday?)? He was "behaving", controlling himself, not wanting to "disturb" or FDA. Orders from the Philippines will "disturb" our FDA. Nader will be like: "well, we didn't want to turn down an opportunity to save lives and receive our first revenue. Hey FDA, the US can buy the remaining vials if they want them."
Any nation ordering LL before the USA, will place heavy pressure on our FDA, a spotlight large question mark. In spite of the FDAs scandalous treatment of Cytodyn, Nader persistently caders to and compliments our FDA because he covets and lusts for their "eventual approval" for a long list of indications.
He was behaving politically and with clever planning IMO, he has no choice other than this one (below) which IMO, is now "off the table":
to wait wait wait for more data while deaths continue and competitors progress and while Cytodyn gets deeper in debt with no revenue and a lot of expenses including expensive trials. Revenue is now probable very soon.
So why wasn't he excited about that on the ProActive video on Thursday (or was it Friday?)? He was "behaving", controlling himself, not wanting to "disturb" or FDA. Orders from the Philippines will "disturb" our FDA. Nader will be like: "well, we didn't want to turn down an opportunity to save lives and receive our first revenue. Hey FDA, the US can buy the remaining vials if they want them."
Any nation ordering LL before the USA, will place heavy pressure on our FDA, a spotlight large question mark. In spite of the FDAs scandalous treatment of Cytodyn, Nader persistently caders to and compliments our FDA because he covets and lusts for their "eventual approval" for a long list of indications.
He was behaving politically and with clever planning IMO, he has no choice other than this one (below) which IMO, is now "off the table":
to wait wait wait for more data while deaths continue and competitors progress and while Cytodyn gets deeper in debt with no revenue and a lot of expenses including expensive trials. Revenue is now probable very soon.
(8)
(0)
